Our NMA strongly supports the advantage of empiric antifungal treatment by indicating that five antifungal agents have a significant lower rate of fungal infection-related mortality than NAT, respectively, in spite of the poor precision of the results. This evidence concerns the gene BRD2 and fungal infectious disease.